Qabil 15mg Tablet

Initial Dose Recommended Dose Maximum Dose Schizophrenia – adults 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia – adolescents 2 mg/day 10 mg/day 30 mg/day Bipolar mania – adults: monotherapy 15 mg/day 15 mg/day 30 mg/day Bipolar mania – adults: adjunct to lithium or valproate 10 to 15 mg/day 15 mg/day 30 mg/day Bipolar mania – pediatric patients: monotherapy or as an adjunct to lithium or valproate 2 mg/day 10 mg/day 30 mg/day Major Depressive Disorder – Adults adjunct to antidepressants 2 to 5 mg/day 5 to 10 mg/day 15 mg/day Irritability associated with autistic disorder – pediatric patients 2 mg/day 5 to 10 mg/day 15 mg/day Tourette’s – Patients < 50 kg 2 mg/day 5 mg/day 10 mg/day Patients ≥ 50 kg 2 mg/day 10 mg/day 20 mg/day Oral formulations: Administer once daily without regard to meals Known CYP2D6 poor metabolizers: Half of the usual dose 2.1 Schizophrenia Adults The recommended starting and target dose for aripiprazole oral solution is 10 or 15 mg/day administered on a once-a-day schedule without regard to meals.

Directions from the U.S. FDA-approved label for Aripiprazole — your doctor or pharmacist may advise differently.

Aripiprazole oral solution is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis. Known hypersensitivity to aripiprazole

Excerpt from the U.S. FDA-approved label for Aripiprazole. Talk to a pharmacist or doctor before use.

Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack, including fatalities) Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring Tardive Dyskinesia: Discontinue if clinically appropriate Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain Hyperglycemia/Diabetes Mellitus: Monitor glucose regularly in patients with and at risk for diabetes Dyslipidemia: Undesirable alterations in lipid levels have been observed in patients treated with atypical antipsychotics Weight Gain: Weight gain has been observed with atypical antipsychotic use.

Warnings and precautions excerpt from the U.S. FDA-approved label for Aripiprazole — not a complete list. Talk to a pharmacist or doctor before use.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Excerpt from the U.S. FDA-approved label for Aripiprazole — not a complete list. Talk to a pharmacist or doctor about side effects.

18 brands · 7 makers in the NepalDoc catalog — see the full Aripiprazole guide →

Storage Oral Solution Store at 20° to 25°C (68° to 77°F);

Storage information from the U.S. FDA-approved label for Aripiprazole.